395 related articles for article (PubMed ID: 36375235)
1. Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist.
Tall Bull S; Nuffer W; Trujillo JM
J Diabetes Complications; 2022 Dec; 36(12):108332. PubMed ID: 36375235
[TBL] [Abstract][Full Text] [Related]
2. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
Karagiannis T; Avgerinos I; Liakos A; Del Prato S; Matthews DR; Tsapas A; Bekiari E
Diabetologia; 2022 Aug; 65(8):1251-1261. PubMed ID: 35579691
[TBL] [Abstract][Full Text] [Related]
3. Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice.
Bradley CL; McMillin SM; Hwang AY; Sherrill CH
Ann Pharmacother; 2023 Jul; 57(7):822-836. PubMed ID: 36367094
[TBL] [Abstract][Full Text] [Related]
4. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
Nauck MA; D'Alessio DA
Cardiovasc Diabetol; 2022 Sep; 21(1):169. PubMed ID: 36050763
[TBL] [Abstract][Full Text] [Related]
5. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Frías JP; Davies MJ; Rosenstock J; Pérez Manghi FC; Fernández Landó L; Bergman BK; Liu B; Cui X; Brown K;
N Engl J Med; 2021 Aug; 385(6):503-515. PubMed ID: 34170647
[TBL] [Abstract][Full Text] [Related]
6. Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide.
Urva S; Levine JA; Schneck K; Tang CC
Curr Med Res Opin; 2024 Apr; 40(4):567-574. PubMed ID: 38407177
[TBL] [Abstract][Full Text] [Related]
7. Tirzepatide in Hispanic/Latino Patients With Type 2 Diabetes: A Subgroup Analysis of the SURPASS Program.
Frías JP; Galindo RJ; Wang H; Malik RE; Chivukula KK; Maldonado JM
J Clin Endocrinol Metab; 2024 Jan; 109(2):557-568. PubMed ID: 37602701
[TBL] [Abstract][Full Text] [Related]
8. Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies.
Lingvay I; Cheng AY; Levine JA; Gomez-Valderas E; Allen SE; Ranta K; Torcello-Gómez A; Thieu VT
Diabetes Obes Metab; 2023 Apr; 25(4):965-974. PubMed ID: 36514843
[TBL] [Abstract][Full Text] [Related]
9. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z
Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322
[TBL] [Abstract][Full Text] [Related]
10. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
Fisman EZ; Tenenbaum A
Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
[TBL] [Abstract][Full Text] [Related]
11. Tirzepatide: A Review in Type 2 Diabetes.
France NL; Syed YY
Drugs; 2024 Feb; 84(2):227-238. PubMed ID: 38388874
[TBL] [Abstract][Full Text] [Related]
12. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
Dahl D; Onishi Y; Norwood P; Huh R; Bray R; Patel H; Rodríguez Á
JAMA; 2022 Feb; 327(6):534-545. PubMed ID: 35133415
[TBL] [Abstract][Full Text] [Related]
13. [Focus on tirzepatide, a dual unimolecular GIP-GLP-1 receptor agonist in type 2 diabetes].
Scheen AJ; Radermecker RP; Paquot N
Rev Med Suisse; 2022 Aug; 18(792):1539-1544. PubMed ID: 36004653
[TBL] [Abstract][Full Text] [Related]
14. Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.
Frías JP
Expert Rev Endocrinol Metab; 2020 Nov; 15(6):379-394. PubMed ID: 33030356
[TBL] [Abstract][Full Text] [Related]
15. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
Ludvik B; Giorgino F; Jódar E; Frias JP; Fernández Landó L; Brown K; Bray R; Rodríguez Á
Lancet; 2021 Aug; 398(10300):583-598. PubMed ID: 34370970
[TBL] [Abstract][Full Text] [Related]
16. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Del Prato S; Kahn SE; Pavo I; Weerakkody GJ; Yang Z; Doupis J; Aizenberg D; Wynne AG; Riesmeyer JS; Heine RJ; Wiese RJ;
Lancet; 2021 Nov; 398(10313):1811-1824. PubMed ID: 34672967
[TBL] [Abstract][Full Text] [Related]
17. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
Gastaldelli A; Cusi K; Fernández Landó L; Bray R; Brouwers B; Rodríguez Á
Lancet Diabetes Endocrinol; 2022 Jun; 10(6):393-406. PubMed ID: 35468325
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: A systematic review and meta-analysis of randomized clinical trials.
Permana H; Yanto TA; Hariyanto TI
Diabetes Metab Syndr; 2022 Nov; 16(11):102640. PubMed ID: 36274410
[TBL] [Abstract][Full Text] [Related]
19. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.
Thomas MK; Nikooienejad A; Bray R; Cui X; Wilson J; Duffin K; Milicevic Z; Haupt A; Robins DA
J Clin Endocrinol Metab; 2021 Jan; 106(2):388-396. PubMed ID: 33236115
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of tirzepatide in people with type 2 diabetes by baseline body mass index: An exploratory subgroup analysis of SURPASS-AP-Combo.
Ma J; Liu M; Wang R; Du L; Ji L
Diabetes Obes Metab; 2024 Apr; 26(4):1454-1463. PubMed ID: 38302718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
